Treatment Information

Back

Liver Cancer treatment details. Biologic therapy.

Massachusetts General Hospital, Boston, MA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Boston, MA
Treatments:Biologic therapyHospital:Massachusetts General Hospital
Drugs:Journal:Link
Date:Mar 2013

Description:

Patients:
This phase 2 study involved 17 advanced hepatocellular carcinoma patients. The median patient age was 66 years and 88% were male.

Treatment:
Patients were treated with the biologic therapy agent called cediranib, which is a tyrosine kinase inhibitor that interferes with tumor blood supply.

Toxicities:
There was one reported death due to brain herniation that may have been related to treatment. Grade 4 pulmonary embolism and grade 3 fatigue were also reported.

Results:
The median overall survival was 11.7 months.

Support:
This study was partially supported by AstraZeneca, makers of cediranib.

Correspondence: Dr. Andrew X. Zhu; email: [email protected]



Back